The role of high-sensitivity C-reactive Protein, interleukin-6 and cystatin C in ischemic stroke complicating atrial fibrillation

Abstract

This study examined the role of high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6) and cystatin C in ischemic stroke complicating atrial fibrillation (AF) and the relationship of systemic inflammation with this disease in order to identify AF patients who are at high risk of stroke and need optimal anticoagulant therapy. A total of 103 AF patients, simple (n=75) or complicated by ischemic stroke (n=28), and 112 control subjects were recruited. IL-6 level was detected by using enzyme linked immunosorbent assay. Cystatin C and hsCRP levels were measured by means of a particle-enhanced immunonephelometric assay. The results showed that the AF patients had higher levels of hsCRP (P=0.004), IL-6 (P=0.000), and cystatin C (P=0.000) than control subjects. Plasma hsCRP level was increased in the AF patients with ischemic stroke as compared to the patients with simple AF (P=0.036). The AF patients who had the level of hsCRP exceeding 3.83 mg/L were at a higher risk than those with hsCRP level lower than 3.83 mg/L (P=0.030). After adjusting for other factors, cystatin C remained positively associated with IL-6 (r=0.613) and hsCRP (r=0.488). It was concluded that hsCRP is positively correlated with ischemic stroke complicating AF and may be a risk factor independent of other risk factors for AF. Elevated cystatin C level is also indicative of the increased risk of AF.

Keywords

C-reactive protein / interleukin-6 / cystatin C / atrial fibrillation / ischemic stroke

References

[1] GoA.S., HylekE.M., PhillipsK.A., et al.. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA, 2001, 285(18): 2370-2375

[2] FurbergC.D., PsatyB.M., ManolioT.A., et al.. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol, 1994, 74(3): 236-241

[3] No authors listed.. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med, 1994, 154(19): 1449-1457

[4] WolfP.A., AbbottR.D., KannelW.B.. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke, 1991, 22(8): 983-988

[5] HartR.G., HalperinJ.L.. Atrial Fibrillation and thromboembolism: A decade of progress in stroke prevention. Ann Intern Med, 1999, 131(9): 688-695

[6] BoosC.J., AndersonR.A., LipG.Y.. Is atrial fibrillation an inflammatory disorder?. Eur Heart J, 2006, 27(2): 136-149

[7] RoldánV., MarínF., MartínezJ.G., et al.. Relation of interleukin-6 levels and prothrombin fragment 1+2 to a point-based score for stroke risk in atrial fibrillation. Am J Cardiol, 2005, 95(7): 881-882

[8] AbdelhadiR.H., GurmH.S., Van WagonerD.R., et al.. Relation of an exaggerated rise in white blood cells after coronary bypass or cardiac valve surgery to development of atrial fibrillation postoperatively. Am J Cardiol, 2004, 93(9): 1176-8

[9] ShlipakM.G., SarnakM.J., KatzR., et al.. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med, 2005, 352(20): 2049-2060

[10] PsychariS.N., ApostolouT.S., SinosL., et al.. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol, 2005, 95(6): 764-767

[11] ChungM.K., MartinD.O., SprecherD., et al.. C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation, 2001, 104(24): 2886-2891

[12] AvilesR.J., MartinD.O., Apperson-HansenC., et al.. Inflammation as a risk factor for atrial fibrillation. Circulation, 2003, 108(24): 3006-3010

[13] ConwayD.S., BugginsP., HughesE., et al.. Relation of interleukin-6, C-reactive protein, and the prothrombotic state to transesophageal echocardiographic findings in atrial fibrillation. Am J Cardiol, 2004, 93(11): 1368-1373

[14] ConwayD.S., BugginsP., HughesE., et al.. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol, 2004, 43(11): 2075-2082

[15] The SPAF III writing committee for the stroke prevention in atrial fibrillation investigators.. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke prevention in atrial fibrillation III study. JAMA, 1998, 279(16): 1273-1277

[16] BenjaminE.J., LevyD., VaziriS.M., et al.. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA, 1994, 271(11): 840-844

[17] ShermanD.G., GoldmanL., WhitingR.B., et al.. Thromboembolism in patients with atrial fibrillation. Arch Neurol, 1984, 41(7): 708-710

[18] The stroke prevention in atrial fibrillation investigators.. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. Ann Intern Med, 1992, 116(1): 1-5

[19] KistlerJ.P., SingerD.E., MillensonM.M., et al.. Effect of low-intensity warfarin anticoagulation on level of activity of the hemostatic system in patients with atrial fibrillation. BAATAF Investigators. Stroke, 1993, 24(9): 1360-1365

[20] FonsecaJ.E., SantosM.J., CanhãoH., et al.. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev, 2009, 8(7): 538-542

[21] YamagamiH., KitagawaK., NagaiY., et al.. Higher levels of interleukin-6 are associated with lower echogenicity of carotid artery plaques. Stroke, 2004, 35(3): 677-681

[22] FillerG., BökenkampA., HofmannW., et al.. Cystatin C as a marker of GFR—history, indications, and future research. Clin Biochem, 2005, 38(1): 1-8

[23] BriguoriC., ViscontiG., RiveraN.V., et al.. Cystatin C and contrast-induced acute kidney injury. Circulation, 2010, 121(19): 2117-2122

[24] NiL., LüJ., HouL.B., et al.. Cystatin C, associated with hemorrhagic and ischemic stroke, is a strong predictor of the risk of cardiovascular events and death in Chinese. Stroke, 2007, 38(12): 3287-3288